A detailed history of Susquehanna International Group, LLP transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 121,222 shares of CPRX stock, worth $2.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
121,222
Previous 84,976 42.65%
Holding current value
$2.5 Million
Previous $1.32 Million 83.05%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$15.19 - $21.35 $550,576 - $773,852
36,246 Added 42.65%
121,222 $2.41 Million
Q2 2024

Aug 15, 2024

SELL
$14.68 - $16.92 $647,755 - $746,595
-44,125 Reduced 34.18%
84,976 $1.32 Million
Q1 2024

May 07, 2024

SELL
$13.18 - $17.11 $704,365 - $914,392
-53,442 Reduced 29.28%
129,101 $2.06 Million
Q4 2023

Feb 14, 2024

BUY
$11.78 - $17.29 $548,606 - $805,212
46,571 Added 34.25%
182,543 $3.07 Million
Q3 2023

Nov 14, 2023

SELL
$11.69 - $15.02 $616,086 - $791,584
-52,702 Reduced 27.93%
135,972 $1.59 Million
Q2 2023

Aug 11, 2023

SELL
$11.5 - $18.08 $73,910 - $116,200
-6,427 Reduced 3.29%
188,674 $2.54 Million
Q1 2023

May 16, 2023

SELL
$14.34 - $21.05 $1.35 Million - $1.98 Million
-94,174 Reduced 32.56%
195,101 $3.23 Million
Q4 2022

Feb 14, 2023

BUY
$12.25 - $19.5 $914,401 - $1.46 Million
74,645 Added 34.78%
289,275 $5.38 Million
Q3 2022

Nov 14, 2022

BUY
$7.06 - $15.52 $1.09 Million - $2.41 Million
155,039 Added 260.17%
214,630 $2.75 Million
Q2 2022

Aug 15, 2022

SELL
$6.23 - $8.57 $323,455 - $444,945
-51,919 Reduced 46.56%
59,591 $418,000
Q1 2022

May 16, 2022

SELL
$5.31 - $8.31 $297,046 - $464,869
-55,941 Reduced 33.41%
111,510 $924,000
Q4 2021

Feb 14, 2022

SELL
$5.21 - $7.45 $140,456 - $200,844
-26,959 Reduced 13.87%
167,451 $1.13 Million
Q3 2021

Nov 15, 2021

SELL
$4.85 - $6.04 $543,665 - $677,059
-112,096 Reduced 36.57%
194,410 $1.03 Million
Q2 2021

Aug 11, 2021

BUY
$4.29 - $6.05 $591,273 - $833,847
137,826 Added 81.71%
306,506 $1.76 Million
Q1 2021

May 17, 2021

BUY
$3.45 - $4.69 $231,267 - $314,389
67,034 Added 65.95%
168,680 $778,000
Q4 2020

Feb 16, 2021

BUY
$2.97 - $3.83 $19,438 - $25,067
6,545 Added 6.88%
101,646 $339,000
Q3 2020

Nov 16, 2020

BUY
$2.97 - $5.08 $156,429 - $267,563
52,670 Added 124.13%
95,101 $282,000
Q2 2020

Aug 14, 2020

SELL
$3.48 - $5.05 $443,626 - $643,768
-127,479 Reduced 75.03%
42,431 $196,000
Q1 2020

May 15, 2020

SELL
$2.61 - $5.21 $66,171 - $132,089
-25,353 Reduced 12.98%
169,910 $654,000
Q4 2019

Feb 14, 2020

SELL
$3.67 - $5.7 $470,754 - $731,144
-128,271 Reduced 39.65%
195,263 $732,000
Q3 2019

Nov 14, 2019

BUY
$3.89 - $7.43 $675,529 - $1.29 Million
173,658 Added 115.87%
323,534 $1.72 Million
Q2 2019

Aug 16, 2019

BUY
$2.7 - $6.11 $14,455 - $32,712
5,354 Added 3.7%
149,876 $576,000
Q2 2019

Aug 14, 2019

BUY
$2.7 - $6.11 $261,748 - $592,327
96,944 Added 203.76%
144,522 $555,000
Q4 2018

Feb 14, 2019

BUY
$1.92 - $3.62 $66,975 - $126,276
34,883 Added 274.78%
47,578 $91,000
Q2 2018

Aug 14, 2018

SELL
$2.26 - $3.84 $52,655 - $89,468
-23,299 Reduced 64.73%
12,695 $40,000
Q4 2017

Feb 14, 2018

BUY
$2.51 - $4.4 $90,344 - $158,373
35,994
35,994 $141,000

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.12B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.